CDC
Cell division cycle 6 (CDC6) is essential for the initiation of DNA replication in eukaryotic cells and is closely related to cell-cycle regulation in cancer[1]. Mechanistically, CDC6 acts through cell-cycle events and the PI3K-AKT pathway, linking DNA replication programs with proliferation, migration, invasion, apoptosis resistance, and immune infiltration[1][3]. In disease models, CDC6 expression was significantly upregulated in PCOS and endometrial cancer, and CDC6 knockdown reduced endometrial cancer cell proliferation, migration, and invasion while increasing apoptosis[1]. In small cell lung cancer datasets, CDC6 appeared among hub genes enriched in cell cycle, DNA replication, oocyte meiosis, and mismatch repair pathways[2]. Compared with related cell-division-cycle markers such as CDC20, CDC6 is supported here by direct functional knockdown evidence in endometrial cancer and hepatocellular carcinoma models[1][2][3]. For experimental applications, CDC6 currently has stronger evidence as a diagnostic, prognostic, immunotherapy, and targeted-therapy biomarker than as a validated agonist or inhibitor target[3].
参考文献:
- [1]. Song Y, et al. Exploring Bioinformatics Tools to Analyze the Role of CDC6 in the Progression of Polycystic Ovary Syndrome to Endometrial Cancer by Promoting Immune Infiltration. Int J Mol Sci. 2024 Dec 3;25(23):12974. [Content Brief]
- [2]. Wen P, et al. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis. Mol Med Rep. 2018 Aug;18(2):1538-1550. [Content Brief]
- [3]. Li C, et al. Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC. Transl Oncol. 2025 Mar;53:102314. [Content Brief]
All Product Categories
-
CDC 関連製品 (21)
関連製品 (21)
- 1
- 2
-
Simurosertib
0 Images別名: TAK-931Simurosertib (TAK-931) is an orally active, selective and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor, with an IC50 of <0.3 nM. Simurosertib has anti-cancer activity.
-
MBQ-167
0 ImagesMBQ-167 is a dual Rac/Cdc42 inhibitor, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.
-
XL413 monohydrochloride
0 Images別名: BMS-863233 monohydrochloride
-
CKI-7 free base
0 ImagesCKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases.
-
CDC25A/NF-κB-IN-1
0 Images製品番号: HY-184446CDC25A/NF-κB-IN-1 is an effective dual-target inhibitor of CDC25A and NF-κB, and is a prodrug of Pt(IV). CDC25A/NF-κB-IN-1 has anticancer activity and low cytotoxicity to normal cells. CDC25A/NF-κB-IN-1 can trigger a variety of anticancer mechanisms, including S phase cell cycle arrest, mitochondrial endogenous apoptosis, endoplasmic reticulum stress, autophagy-dependent ferroptosis. CDC25A/NF-κB-IN-1 has good safety and can be used for ovarian cancer research.
-
LY3177833
0 ImagesLY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducer.
-
CKI-7
0 ImagesCKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases.
-
(S)-LY3177833 hydrate
0 Images製品番号: HY-143430ACAS 番号: 2733342-93-1(S)-LY3177833 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor. (S)-LY3177833 hydrate shows broad in vitro anticancer activity.
-
LY3177833 monhydrate
0 Images製品番号: HY-100023ACAS 番号: 1627696-53-0LY3177833 (Example 4) monhydrate is an orally active CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively. LY3177833 monhydrate is a senescence inducer.
-
(S)-LY3177833
0 Images製品番号: HY-143430CAS 番号: 1627696-52-9(S)-LY3177833 ((S)-Example 2) is an orally active CDC7 kinase inhibitor. (S)-LY3177833 shows broad in vitro anticancer activity.
-
Cdc7-IN-15
0 Images製品番号: HY-143429CAS 番号: 1244027-03-9Cdc7-IN-15 (Example 108) is a cdc7 kinase inhibitor. Cdc7-IN-15 can be used for cancer research.
-
XL413 hydrochloride
0 Images製品番号: HY-15260CCAS 番号: 1169562-71-3別名: BMS-863233 hydrochlorideXL413 (BMS-863233) hydrochloride is an orally active and selective CDC7 inhibitor (IC50=3.4 nM). XL413 hydrochloride has favorable pharmacokinetic profiles and significantly inhibits tumor growth in rodent models. XL413 hydrochloride can be used in cancer research.
-
Cdc7-IN-14
0 Images製品番号: HY-143389CAS 番号: 2764866-21-7Cdc7-IN-14 (compound 82) is a potent CDC7 inhibitor with an IC50 of <1 nM. Cdc7-IN-14 has the potential for the research of cancer.
-
Cdc7-IN-13
0 Images製品番号: HY-143387CAS 番号: 2764866-23-9Cdc7-IN-13 (compound 84) is a potent CDC7 inhibitor with an IC50 of <1 nM. Cdc7-IN-13 has the potential for the research of cancer.
-
Cdc7-IN-18
0 Images製品番号: HY-143432CAS 番号: 2562329-14-8Cdc7-IN-18 (compound 1-2) is a potent CDC7 inhibitor with an IC50 of 1.29 nM for Cdc7/DBF4 enzyme. Cdc7-IN-18 shows antiproliferative activities with IC50 of 53.62 nM in COLO205 cells.
-
Cdc7-IN-12
0 Images製品番号: HY-143385CAS 番号: 2764865-33-8Cdc7-IN-12 (compound 1) is a potent CDC7 inhibitor with an IC50 of <1 nM. Cdc7-IN-12 shows antiproliferative activities with IC50 of 100-1000 nM in COLO205 cells. Cdc7-IN-12 has the potential for the research of cancer.
-
PSTAIR
0 Images製品番号: HY-P3893CAS 番号: 126675-53-4PSTAIR is a monoclonal antibody that recognizes the PSTAIR sequence in Cdc28, PSTAIR can be used as loading control.
-
Cdc7-IN-19
0 Images製品番号: HY-143433CAS 番号: 2606780-39-4Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC50 of 1.49 nM.
- 1
- 2
